Global Medical REIT Updates Principal Office Address

TL;DR

GMRE moved its main office to Bethesda, MD.

AI Summary

Global Medical REIT Inc. filed an 8-K on March 5, 2024, reporting an event on February 27, 2024. The filing indicates a change in the company's principal executive offices to 7373 Wisconsin Avenue, Suite 800, Bethesda, MD 20814. This is a routine update for the real estate investment trust.

Why It Matters

This filing signifies a change in the company's operational headquarters, which could be relevant for investors and partners needing to update their contact information.

Risk Assessment

Risk Level: low — This is a standard administrative filing regarding a change of address, with no immediate financial or operational risks indicated.

Key Players & Entities

• Global Medical REIT Inc. (company) — Registrant
• 7373 Wisconsin Avenue, Suite 800, Bethesda, MD 20814 (location) — New Principal Executive Offices
• February 27, 2024 (date) — Earliest event reported
• March 5, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — h registered: Common Stock, par value $0.001 per share GMRE NYSE Series A Pref

Filing Documents

• tm247999d1_8k.htm (8-K) — 27KB
• tm247999d1_ex5-1.htm (EX-5.1) — 28KB
• tm247999d1_ex5-1img01.jpg (GRAPHIC) — 15KB
• tm247999d1_ex5-1img02.jpg (GRAPHIC) — 8KB
• 0001104659-24-031048.txt ( ) — 306KB
• gmre-20240227.xsd (EX-101.SCH) — 3KB
• gmre-20240227_def.xml (EX-101.DEF) — 26KB
• gmre-20240227_lab.xml (EX-101.LAB) — 36KB
• gmre-20240227_pre.xml (EX-101.PRE) — 25KB
• tm247999d1_8k_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. On February 27, 2024, Global Medical REIT Inc. (the "Company") filed a prospectus supplement (the "Prospectus Supplement") in connection with its "at-the-market" offering program (the "ATM Program") pursuant to the Company's registration statement on Form S-3ASR (File No. 333-276248) (the "WKSI Shelf"), as amended by Post-Effective Amendment No. 1 thereto (the "Post-Effective Amendment"), previously filed with the Securities and Exchange Commission. The Company filed the Prospectus Supplement solely to move the ATM Program from the WKSI Shelf to the Post-Effective Amendment, which Post-Effective Amendment was filed because the Company no longer qualified as a "well-known seasoned issuer" (as such term is defined in Rule 405 of the Securities Act of 1933, as amended) when it filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The opinion of Venable LLP, counsel to the Company, is filed as Exhibit 5.1 to this Report and is incorporated by reference to the Prospectus Supplement.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Venable LLP. 23.1 Consent of Venable LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Global Medical REIT Inc. By: /s/ Jamie A. Barber Jamie A. Barber Secretary and General Counsel Date: March 5, 2024

View Full Filing

View this 8-K filing on SEC EDGAR